Approval · Notice of Compliance 35757 · 2025
POMALYST: Notice of Compliance 35757
Issued July 28, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35757
- Date
- July 28, 2025
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter. Product Monograph reformatted to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| POMALYST | Not yet assigned | — |
Medicinal ingredients
- POMALIDOMIDE 1 MG per CAP
- POMALIDOMIDE 2 MG per CAP
- POMALIDOMIDE 3 MG per CAP
- POMALIDOMIDE 4 MG per CAP